Accès gratuit
Volume 25, Numéro 4, Juillet 2016
Médecine interne et transversalité
Page(s) 400 - 407
Section Mise au Point / Update
Publié en ligne 8 juin 2016
  • Banerji A, Clark S, Blanda M, et al (2008) Multicenter study of patients with angiotensin-converting enzyme inhibitor-induced angioedema who present to the emergency department. Ann Allergy Asthma Immunol 100:327–32 [CrossRef] [PubMed] [Google Scholar]
  • Bork K, Hardt J, Schicketanz KH, Ressel N (2003) Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency. Arch Intern Med 163:1229–35 [CrossRef] [PubMed] [Google Scholar]
  • Fremeaux-Bacchi V, Guinnepain MT, Cacoub P, et al (2002) Prevalence of monoclonal gammopathy in patients presenting with acquired angioedema type II. Am J Med 113:194–9 [CrossRef] [PubMed] [Google Scholar]
  • Cicardi M, Aberer W, Banerji A, et al (2014) Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy 69:602–16 [CrossRef] [PubMed] [Google Scholar]
  • Bork K, Siedlecki K, Bosch S, et al (2000) Asphyxiation by laryngeal edema in patients with hereditary angioedema. Mayo Clin Proc 75:349–54 [CrossRef] [PubMed] [Google Scholar]
  • Bork K, Staubach P, Eckardt AJ, Hardt J (2006) Symptoms, course, and complications of abdominal attacks in hereditary angioedema due to C1 inhibitor deficiency. Am J Gastroenterol 101:619–27 [CrossRef] [PubMed] [Google Scholar]
  • Guichon C, Floccard B, Coppere B, et al (2011) One hypovolaemic shock… two kinin pathway abnormalities. Intensive Care Med 37:1227–8 [CrossRef] [PubMed] [Google Scholar]
  • Zuraw BL (2008) Clinical practice. Hereditary angioedema. N Engl J Med 359:1027–36 [CrossRef] [PubMed] [Google Scholar]
  • Cicardi M, Bork K, Caballero T, et al (2012) Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy 67:147–57 [CrossRef] [PubMed] [Google Scholar]
  • Longhurst H, Cicardi M (2012) Hereditary angio-oedema. Lancet 379:474–81 [CrossRef] [PubMed] [Google Scholar]
  • Javaud N, Gompel A, Bouillet L, et al (2015) Factors associated with hospital admission in hereditary angioedema attacks: a multicenter prospective study. Ann Allergy Asthma Immunol 114:499–503 [CrossRef] [PubMed] [Google Scholar]
  • Bork K, Hardt J, Witzke G (2012) Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. J Allergy Clin Immunol 130:692–7 [CrossRef] [PubMed] [Google Scholar]
  • Craig TJ, Bewtra AK, Bahna SL, et al (2011) C1 esterase inhibitor concentrate in 1,085 hereditary angioedema attacks — final results of the IMPACT 2 study. Allergy 66:1604–11 [CrossRef] [PubMed] [Google Scholar]
  • Bowen T, Cicardi M, Farkas H, et al (2010) 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol 6:24 [CrossRef] [PubMed] [Google Scholar]
  • Cicardi M, Zingale LC, Bergamaschini L, Agostoni A (2004) Angioedema associated with angiotensin-converting enzyme inhibitor use: outcome after switching to a different treatment. Arch Intern Med 164:910–3 [CrossRef] [PubMed] [Google Scholar]
  • Kostis JB, Kim HJ, Rusnak J, et al (2005) Incidence and characteristics of angioedema associated with enalapril. Arch Intern Med 165:1637–42 [CrossRef] [PubMed] [Google Scholar]
  • Miller DR, Oliveria SA, Berlowitz DR, et al (2008) Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors. Hypertension 51:1624–30 [CrossRef] [PubMed] [Google Scholar]
  • Pfeffer MA, McMurray JJ, Velazquez EJ, et al (2003) Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349:1893–906 [CrossRef] [PubMed] [Google Scholar]
  • Haymore BR, Yoon J, Mikita CP, et al (2008) Risk of angioedema with angiotensin receptor blockers in patients with prior angioedema associated with angiotensin-converting enzyme inhibitors: a meta-analysis. Ann Allergy Asthma Immunol 101:495–9 [CrossRef] [PubMed] [Google Scholar]
  • Blacher J, Halimi JM, Hanon O, et al (2014) Management of hypertension in adults: the 2013 French Society of Hypertension guidelines. Fundam Clin Pharmacol 28:1–9 [CrossRef] [Google Scholar]
  • Marant C, Romon I, Fosse S, et al (2008) French medical practice in type II diabetes: the need for better control of cardiovascular risk factors. Diabetes Metab 34:38–45 [CrossRef] [PubMed] [Google Scholar]
  • Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, et al (1994) Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 90:583–612 [CrossRef] [PubMed] [Google Scholar]
  • Bluestein HM, Hoover TA, Banerji AS, et al (2009) Angiotensin-converting enzyme inhibitor-induced angioedema in a community hospital emergency department. Ann Allergy Asthma Immunol 103:502–7 [CrossRef] [PubMed] [Google Scholar]
  • Brown NJ, Byiers S, Carr D, et al (2009) Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema. Hypertension 54:516–23 [CrossRef] [PubMed] [Google Scholar]
  • Duerr M, Glander P, Diekmann F, et al (2010) Increased incidence of angioedema with ACE inhibitors in combination with mTOR inhibitors in kidney transplant recipients. Clin J Am Soc Nephrol 5:703–8 [CrossRef] [PubMed] [Google Scholar]
  • Bova M, Guilarte M, Sala-Cunill A, et al (2015) Treatment of ACEI-related angioedema with icatibant: a case series. Intern Emerg Med 10:345–50 [CrossRef] [PubMed] [Google Scholar]
  • Baş M, Greve J, Stelter K, et al (2015) A randomized trial of icatibant in ACE-inhibitor-induced angioedema. N Engl J Med 372:418–25 [CrossRef] [PubMed] [Google Scholar]
  • Roberts JR, Lee JJ, Marthers DA (2012) Angiotensin-converting enzyme (ACE) inhibitor angioedema: the silent epidemic. Am J Cardiol 109:774–5 [CrossRef] [PubMed] [Google Scholar]
  • Javaud N, Achamlal J, Reuter PG, et al (2015) Angioedema related to angiotensin-converting enzyme inhibitors: attack severity, treatment, and hospital admission in a prospective multicenter study. Medicine (Baltimore) 94:e1939 [CrossRef] [PubMed] [Google Scholar]
  • Dean DE, Schultz DL, Powers RH (2001) Asphyxia due to angiotensin converting enzyme (ACE) inhibitor mediated angioedema of the tongue during the treatment of hypertensive heart disease. J Forensic Sci 46:1239–43 [PubMed] [Google Scholar]
  • Wilson DA, Bork K, Shea EP, et al (2010) Economic costs associated with acute attacks and long-term management of hereditary angioedema. Ann Allergy Asthma Immunol 104:314–20.e2 [CrossRef] [PubMed] [Google Scholar]
  • Aygören-Pürsün E, Bygum A, Beusterien K, et al (2014) Socioeconomic burden of hereditary angioedema: results from the hereditary angioedema burden of illness study in Europe. Orphanet J Rare Dis 9:99 [CrossRef] [PubMed] [Google Scholar]
  • Martinez-Saguer I, Rusicke E, Aygoren-Pursun E, et al (2010) Characterization of acute hereditary angioedema attacks during pregnancy and breast-feeding and their treatment with C1 inhibitor concentrate. Am J Obstet Gynecol 203:131.e1–7 [CrossRef] [Google Scholar]
  • Bouillet L, Lehmann A, Gompel A, et al (2015) Hereditary angiœdema treatments: recommendations from the French National Center for Angiœdema (Bordeaux consensus 2014). Presse Med 44:526–32 [CrossRef] [PubMed] [Google Scholar]
  • Zuraw BL, Busse PJ, White M, et al (2010) Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 363:513–22 [CrossRef] [PubMed] [Google Scholar]
  • Cicardi M, Banerji A, Bracho F, et al (2010) Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 363:532–41 [CrossRef] [PubMed] [Google Scholar]
  • Bork K (2010) Diagnosis and treatment of hereditary angioedema with normal C1 inhibitor. Allergy Asthma Clin Immunol 6:15 [CrossRef] [PubMed] [Google Scholar]
  • Wintenberger C, Boccon-Gibod I, Launay D, et al (2014) Tranexamic acid as maintenance treatment for non-histaminergic angioedema: analysis of efficacy and safety in 37 patients. Clin Exp Immunol 178:112–7 [CrossRef] [Google Scholar]
  • Nielsen EW, Gramstad S (2006) Angioedema from angiotensin-converting enzyme (ACE) inhibitor treated with complement 1 (C1) inhibitor concentrate. Acta Anaesthesiol Scand 50:120–2 [CrossRef] [PubMed] [Google Scholar]
  • Rasmussen ER, Bygum A (2013) ACE-inhibitor induced angio-oedema treated with complement C1 inhibitor concentrate. BMJ Case Rep pii: bcr2013200652 [Google Scholar]
  • Nosbaum A, Bouillet L, Floccard B, et al (2013) Management of angiotensin-converting enzyme inhibitor-related angioedema: recommendations from the French National Center for Angioedema. Rev Med Interne 34:209–13 [CrossRef] [PubMed] [Google Scholar]
  • Javaud N, Karami A, Stirnemann J, et al (2013) Bradykinin-mediated angioedema: factors prompting ED visits. Am J Emerg Med 31:124–9 [CrossRef] [PubMed] [Google Scholar]
  • Javaud N, Lapostolle F, Sapir D, et al (2013) The early treatment of bradykinin angioedema, a challenge for emergency medicine. Eur J Emerg Med 20:291–2 [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.